Manufacturing Change Must Be Validated Before Drug Distribution - FDA Rule
This article was originally published in The Tan Sheet
Executive Summary
Drug companies must validate that a change in manufacturing has not significantly altered a drug product prior to distribution of the product following the change, FDA's proposed rule on "Supplements and Other Changes to an Approved Application" states.
You may also be interested in...
Packaging Component List For Approved Drugs Could Ease PAC Filings
FDA and the pharmaceutical industry should draft a list of "CDER-approved" container closure components as a supplement to the upcoming packaging post-approval changes guidance, participants recommended at an FDA/American Association of Pharmaceutical Scientists workshop on packaging and analytical method post-approval changes.
Packaging Component List For Approved Drugs Could Ease PAC Filings
FDA and the pharmaceutical industry should draft a list of "CDER-approved" container closure components as a supplement to the upcoming packaging post-approval changes guidance, participants recommended at an FDA/American Association of Pharmaceutical Scientists workshop on packaging and analytical method post-approval changes.
FDA Should Scrap Manufacturing Changes Proposed Rule, Guidance - PhRMA
FDA's proposed rule "Supplements and Other Changes to an Approved Application" and its accompanying guidance should be abandoned, the Pharmaceutical Research & Manufacturers of America asserted in Aug. 27 comments to the agency.